Aave’s launch on Mantle strengthens its presence in high-growth L2 ecosystems, but a new Temp Check reveals the DAO is preparing to wind down several chains.Aave’s launch on Mantle strengthens its presence in high-growth L2 ecosystems, but a new Temp Check reveals the DAO is preparing to wind down several chains.
Aave expands to Mantle — even as the DAO prepares to shut down low-revenue chains
Per feedback o dubbi su questo contenuto, contattateci all'indirizzo crypto.news@mexc.com.
Aave’s launch on Mantle strengthens its presence in high-growth L2 ecosystems, but a new Temp Check reveals the DAO is preparing to wind down several chains.
Disclaimer: gli articoli ripubblicati su questo sito provengono da piattaforme pubbliche e sono forniti esclusivamente a scopo informativo. Non riflettono necessariamente le opinioni di MEXC. Tutti i diritti rimangono agli autori originali. Se ritieni che un contenuto violi i diritti di terze parti, contatta crypto.news@mexc.com per la rimozione. MEXC non fornisce alcuna garanzia in merito all'accuratezza, completezza o tempestività del contenuto e non è responsabile per eventuali azioni intraprese sulla base delle informazioni fornite. Il contenuto non costituisce consulenza finanziaria, legale o professionale di altro tipo, né deve essere considerato una raccomandazione o un'approvazione da parte di MEXC.
Potrebbe anche piacerti
Triple-A Integrates with Circle Payments Network to Support Cross-Border Stablecoin Settlement
Triple-A, a licensed global financial institution, announced that it has integrated with Circle Payments Network (CPN), operated by Circle Technology Services,
Condividi
Globalfintechseries2026/03/25 22:33
Trump's airport move just laid bare a massive MAGA lie: columnist
After months of saying that ICE agents need to wear masks so they don't get doxxed, President Donald Trump said this week that they should not wear masks while
Condividi
Rawstory2026/03/25 23:22
Sarepta Therapeutics (SRPT) Stock Climbs Following Positive siRNA Muscular Dystrophy Trial Results
Sarepta (SRPT) stock rises on positive Phase 1/2 siRNA trial data showing muscle delivery, biomarker activity, and safety in rare muscular dystrophy programs. The
Condividi
Blockonomi2026/03/25 23:05
